RxDoctor Payments DataLook up a doctor →

Samer Homsi, MD

Pulmonary Disease · Little Rock, ARNPI 1366604902

Payments from drug & device makers

$9,410in general payments, 2019–2025

Across 548 payments — averaging $17.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • AstraZeneca$2K
  • Boehringer Ingelheim$1K
  • Mallinckrodt Hospital Products Inc.$538
  • Electromed, Inc.$521
  • Sanofi$432
  • plus $3K from 28 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,410 in reported general payments places this provider in the 75th percentile of 102 pulmonary disease providers in Arkansas.

See all pulmonary disease providers in Arkansas

Medicare billing

Part B allowed, 2024
$626,203
Medicare patients
979
Services billed
15,982

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pulmonary disease in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →